Shots:
- Bayer has reported the P-III (FIND-CKD) trial data assessing Kerendia (finerenone; 10 or 20mg) vs PBO, both in addition to SoC, in >1,500 adults with non-diabetic chronic kidney disease
- Trial met its 1EP, showing a statistically significant improvement in eGFR slope, defined as the mean annual change in eGFR from baseline to Month 32; data will be presented at a future conference & submitted to global health authorities for potential approval in this indication
- Additionally, Kerendia/Firialta is under regulatory review in China & EU for heart failure pts having a left ventricular ejection fraction (LVEF) of ≥40%
Ref: Bayer | Image: Bayer | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
